

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/011768 A1

- (51) International Patent Classification⁷: **A61L 29/16**, 29/10, 31/16, 31/08
- (21) International Application Number: PCT/US2004/024558
- (22) International Filing Date: 29 July 2004 (29.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 10/631,871 31 July 2003 (31.07.2003) US
- (71) Applicant (for all designated States except US): **SCIMED LIFE SYSTEMS, INC.** [US/US]; One SciMed Place, Maple Grove, MN 55331-1566 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **TAN, Sharon, Mi, Lyn** [MY/US]; 164 Strathmore Road, Brighton, MA 02135 (US).
- (74) Agents: **BONHAM, David, B.** et al.; Mayer Fortkort & Williams, PC, 251 North Avenue West, 2nd Floor, Westfield, NJ 07090 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2005/011768 A1

(54) Title: LATEX MEDICAL ARTICLES FOR RELEASE OF ANTIMICROBIAL AGENTS

(57) Abstract: According to an aspect of the present invention, a medical article is provided which comprises a latex antimicrobial region. The latex antimicrobial region can constitute the entirety of the medical article, or it can constitute only a portion of the medical article. The latex antimicrobial region comprises releasemodulating microparticles, which are dispersed within a latex polymer. The release-modulating microparticles further comprise an antimicrobial agent, and the microparticles are adapted to release the antimicrobial agent. Examples of medical articles that can be produced in accordance with the present invention are gloves, finger cots, supply and drainage tubes, catheters, condoms, and contraceptive diaphragms. Also described are methods for forming such articles.

LATEX MEDICAL ARTICLES FOR RELEASE
OF ANTIMICROBIAL AGENTS

FIELD OF THE INVENTION

[0001] This invention relates to antimicrobial latex compositions. More particularly, the present invention relates to antimicrobial latex compositions suitable for use in connection with medical articles and having sustained antimicrobial activity.

BACKGROUND OF THE INVENTION

[0002] Numerous latex medical articles are known, which are required to sustain their aseptic properties over a prolonged period of time. One solution to this problem is to produce a medical article containing a dispersed antimicrobial agent, which releases the antimicrobial agent over an extended period.

[0003] It is known that certain heavy metals such as gold, silver, copper and zinc as well as compounds thereof exert an antimicrobial effect upon a wide spectrum of microorganisms, including various bacteria and fungi, at very low metal ion concentrations. This effect is called an oligodynamic effect. Moreover, medical devices have been produced which take advantage of this effect. See, e.g., U.S. Patent No. 4,902,503, the disclosure of which is incorporated by reference.

[0004] Nonetheless, there is continuing need for antimicrobial latex medical articles containing antimicrobial agents, which are released from the articles in a sustained fashion so as to maintain the antimicrobial properties of the same.

SUMMARY OF THE INVENTION

[0005] The above and other needs in the art are addressed by the medical articles of the present invention.

[0006] According to an aspect of the present invention, a medical article is provided which comprises a latex antimicrobial region. The latex antimicrobial region comprises release-modulating microparticles, which are dispersed within a latex polymer. The release-modulating microparticles further comprise an antimicrobial agent and are adapted to release the antimicrobial agent.

[0007] Some examples of medical articles that can be produced in accordance with

the present invention are gloves, finger cots, supply and drainage tubes, catheters, condoms, and contraceptive diaphragms.

[0008] In certain embodiments, the microparticles comprise an encapsulating layer, for example, a polymer-containing layer, surrounding a region that comprises an antimicrobial agent, for example, an antimicrobial-agent-containing core.

[0009] In certain other embodiments, the microparticles comprise a material within which the antimicrobial compound is dispersed. The material can be, for example, a polymeric material or an inorganic material.

[0010] Antimicrobial agents providing silver ions, for example, silver-containing zeolite particles, are used in certain embodiments.

[0011] The latex polymer can be formed from various latexes (or "latices"), which can be, for example, natural or synthetic.

[0012] Other aspects of the invention concern processes for forming the antimicrobial regions of the present invention. For example, an antimicrobial region can be formed by a process that comprises: (a) providing a latex that contains the above release-modulating microparticles, (b) contacting this latex with a substrate, and (c) curing the latex, thereby forming the antimicrobial region. The substrate can be, for example, a mold, which is dipped into the latex.

[0013] The present invention is advantageous in that medical articles can be provided, which reduce the potential for infection upon contact with the body of a subject.

[0014] Another advantage of the present invention is that latex medical articles can be provided in which the therapeutic agent is dispersed throughout the medical article.

[0015] Yet another advantage of the present invention is that latex medical articles can be provided, which release antimicrobial agent over a prolonged period of time.

[0016] These and other embodiments and advantages of the present invention will become immediately apparent to those of ordinary skill in the art upon review of the Detailed Description and Claims to follow.

DETAILED DESCRIPTION OF THE INVENTION

[0017] According to an aspect of the present invention, a medical article is provided which comprises a latex antimicrobial region. The latex antimicrobial region can constitute the entirety of the medical article, or it can constitute only a portion of the

medical article. The latex antimicrobial region comprises release-modulating microparticles, which are dispersed within a latex polymer. The release-modulating microparticles further comprise an antimicrobial agent, and they are adapted to modulate the release of the antimicrobial agent.

[0018] A wide range of microparticle loadings can be used in connection with the medical articles of the present invention, with the amount of loading being readily determined by those of ordinary skill in the art. Microparticle loadings can range, for example, from 0.1 to 40 wt%.

[0019] By "microparticle" is meant a small particle, typically ranging from 0.01 to 1000 microns in largest dimension, more typically 0.1 to 100 microns. The microparticles can be of any shape, including spherical, elongated, irregular, etc.

[0020] The medical articles for use in conjunction with the present invention are typically medical articles that are adapted for contact with a patient, for example, a vertebrate animal, preferably a human. Medical articles for use in conjunction with the present invention include surgical gloves, examination gloves, finger cots, supply and drainage tubes, catheter balloons, uterine thermal ablation balloons, catheter cuffs, condoms, contraceptive diaphragms, in-dwelling urinary drainage catheters, male external urinary drainage catheters, and so forth.

[0021] As used herein a "latex polymer" is a polymer, which is formed from a latex. "Latex," as the term is used herein, is an aqueous polymer dispersion. By "aqueous polymer dispersion" is meant a dispersion of polymer particles in a water-containing fluid.

[0022] Various methods are known for producing latexes (or "latices"), which can be used in connection with the present invention. Latexes can be, for example, (a) derived from natural sources, in which case the latex is commonly referred to as a "natural latex," (b) prepared by emulsion polymerization, in which case the resulting product is commonly referred to as a "synthetic latex", or (c) prepared from a previously formed polymer, in which case the resulting product is commonly referred to as a "synthetic pseudolatex."

[0023] Latices for use in connection with the present invention can be formed from a variety of polymers. For example, the polymer may be a homopolymer or a copolymer (including alternating, random and block copolymers), cyclic, linear or branched (e.g.,

polymers have star, comb or dendritic architecture), natural or synthetic. The polymers for use in connection with the present invention are typically biostable polymers. A biostable polymer is one that maintains its structural integrity, at least for the time period during which the medical device is in contact with the body.

[0024] Accordingly, polymers for latices useful in connection with the present invention include natural polymers and synthetic polymers, examples of which include homopolymers and copolymers of vinyl monomers and diene monomers, for instance, ethylene, styrene, isobutylene, vinyl acetate, vinyl chloride, vinylidene chloride, acrylonitrile, methacrylate, vinyl pyridine, methyl vinyl ether, butadiene, carboxylated butadiene, neoprene, isoprene (natural polyisoprene is a common example), chloroprene, 1,3-pentadiene, 1,5-hexadiene, 1,6-heptadiene, as well as blends and copolymers (e.g., acrylonitrile-butadiene or styrene-isobutylene copolymers) thereof.

[0025] Antimicrobial agents useful for the practice of the present invention include triclosan, chlorhexidine, nitrofurazone, benzalkonium chlorides, and silver ions. Sources for silver ions include numerous silver-containing antimicrobial agents such as silver protein; silver salts such as silver bromide, silver fluoride, silver lactate and silver nitrate; as well as other sources of silver ions including silver-based ion-exchange materials such as silver-ion containing zeolites available as ZEOMIC® from Sinanen Zeomic Co. Ltd., Nagoya, Japan and AgION™ from AgION Technologies, Inc., silver-based glasses such as IONPURE® silver-substituted glasses available from Ishizuka Glass Co., Tokyo, Japan, NOVARON, silver zirconium phosphate available from Taogosei, Nagoya, Japan and AlphaSan® silver-based zirconium phosphates available from Milliken & Company, Spartanburg, SC, USA; as well as other silver-based inorganic compounds such as IRGAGUARD™ B5000 from Ciba Specialty Chemicals, Basel, Switzerland, JMAC™, porous sintered rutile titanium dioxide containing silver chloride, available from Johnson Matthey, United Kingdom, and MircoFree® inorganic particles from DuPont, which contain silver on a core of zinc oxide or contain silver/copper oxide/zinc sulfate on a core of titanium dioxide or barium sulfate.

[0026] As noted above, the selected antimicrobial agent is provided in association with release-modulating microparticles. For instance, in certain embodiments of the invention, the selected antimicrobial agent is provided in association with release-

modulating microparticles, which can comprise, for example, a polymeric shell that encapsulates the antimicrobial agent, a polymeric matrix within which the antimicrobial agent is dispersed, or both. Techniques for providing such microparticles include solvent evaporation or extraction (typically in connection with emulsification, e.g., single or double emulsion techniques), coacervation (including simple and complex coacervation), hot melt encapsulation, interfacial crosslinking, interfacial polymerization, spray drying, and so forth. Such techniques are well known. See, e.g., U.S. Patent Appln. No. 20020160109, which is incorporated by reference.

[0027] Numerous polymers can be used in connection such release-modulating microparticles, including the polymers listed above. Additional exemplary polymers, not necessarily exclusive of the above polymers, include the following: polyolefins such as metallocene catalyzed polyethylenes, polypropylenes, and polybutylenes and copolymers thereof; vinyl aromatic polymers such as polystyrene; vinyl aromatic copolymers such as styrene-isobutylene copolymers and butadiene-styrene copolymers; ethylenic copolymers such as ethylene vinyl acetate (EVA), ethylene-methacrylic acid and ethylene-acrylic acid copolymers where some of the acid groups have been neutralized with either zinc or sodium ions (commonly known as ionomers); polyacetals; chloropolymers such as polyvinylchloride (PVC); fluoropolymers such as polytetrafluoroethylene (PTFE); polyesters such as polyethyleneterephthalate (PET); polyester-ethers; polyamides such as nylon 6 and nylon 6,6; polyamide ethers; polyethers; elastomers such as elastomeric polyurethanes and polyurethane copolymers; silicones; polycarbonates; and mixtures or copolymers of any of the foregoing.

[0028] As seen from the above, the release-modulating microparticles can comprise a polymer-containing shell or matrix to influence release. In other embodiments, the antimicrobial agent is released from microparticles that comprise inorganic materials. Examples include microparticles formed from inorganic, silver-based, ion-exchange materials such as those discussed above, for instance, silver-ion containing zeolites, silver-based glasses, silver-based zirconium phosphates, and sintered titanium dioxide/silver chloride. In each of these examples, the antimicrobial agent (i.e., silver ions) is released from an inorganic material (e.g., zeolites, glasses, zirconium phosphates, porous titanium dioxide).

[0029] Once selected, the latex and the antimicrobial-agent releasing microparticles

are typically combined using any of a number of methods including, for example, simple mixing. If desired, the latex can be provided with numerous supplemental agents known in the art, including pH adjustors, curing agents, curing accelerators, vulcanization agents, softening agents, bulking agents, antioxidants, colorants, coacervating agents, cationic, anionic, zwitterionic and nonionic surfactants, and so forth.

[0030] The mixture is then applied to a suitable substrate (e.g., a medical device substrate or a mold) using any of a variety of techniques including casting techniques; spin coating techniques, web coating techniques, spraying techniques, dipping techniques, techniques involving coating via mechanical suspension, including air suspension, and combinations of these processes. Subsequently, water is either removed or allowed to evaporate from the resulting product, forming a latex polymer. In many embodiments, the latex polymer is cured by heating. In such embodiments, silver-containing antimicrobial agents are advantageous in that they can withstand high curing temperatures, without an associated loss in efficacy.

[0031] A specific embodiment of the present invention will now be described, in which dip-molding of a medical article is performed. In this embodiment, a latex is utilized which comprises a natural rubber latex admixed with silver-containing zeolite particles. Among other constituents, vulcanization agents, for example, sulfur-containing compounds, may be added to promote vulcanization. Where natural rubber latex is utilized, proteins from its natural source typically remain in the rubber. Hence, natural rubber latices are often treated to reduce their protein content. One method of achieving this is by washing with water. For example, a double centrifuge processing method is known in which a first centrifuge step removes some of the aqueous phase from the natural rubber latex, followed by the addition of water and a second centrifuge step to remove the added water and additional protein as well. Other methods are known for reducing protein content that involve the use of enzymes to digest the proteins.

[0032] A mold, for example, one formed from ceramic or metal, is dipped in the latex, followed by removal of the water, which is assisted by heating the mold. If desired, the dipping and water removal may be performed in repeated cycles to increase film thickness, if desired. Moreover, the thickness of the final medical article is also increased in some embodiments though the use of a coagulant, which is also applied by dipping, either before or after the latex dipping step, usually before.

[0033] The film thus formed is then typically vulcanized to bring the rubber to a cured state. In some embodiments, pre-vulcanization (i.e., vulcanization of the rubber in the latex medium prior to the dipping step) is practiced. A film from a pre-vulcanized latex dipping medium does not require vulcanization after the dipping step, but instead only drying to remove the water. In some procedures, both pre- and post-vulcanization are used. Subsequently, the resulting product is removed from the mold. (In some embodiments, a powder such as cornstarch is applied to the mold to assist with release of the product from the mold.)

[0034] This procedure can be used to form any number of medical articles. In one particular embodiment, the procedure is used to create a latex balloon sleeve for a catheter.

[0035] Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.

IN THE CLAIMS:

1. A medical article that comprises an antimicrobial region, said antimicrobial region comprising release-modulating microparticles dispersed within a latex polymer, said release-modulating microparticles comprising an antimicrobial agent and being adapted to release the antimicrobial agent.
2. The medical article of claim 1, wherein said medical article is selected from gloves, finger cots, supply and drainage tubes, catheters, condoms and contraceptive diaphragms.
3. The medical article of claim 1, wherein said medical article is a balloon catheter.
4. The medical article of claim 3, wherein said antimicrobial region is a balloon sleeve.
5. The medical article of claim 1, wherein said antimicrobial region is heat cured.
6. The medical article of claim 5, wherein said antimicrobial region is vulcanized.
7. The medical article of claim 1, wherein said microparticles comprise an encapsulating region that surrounds a region comprising said antimicrobial agent.
8. The medical article of claim 1, wherein said microparticles comprise a core and an encapsulating layer surrounding said core, wherein said core comprises said antimicrobial agent, and wherein said encapsulating layer comprises a polymer.
9. The medical article of claim 1, wherein said microparticles comprise a polymer, and wherein said antimicrobial compound is dispersed within said polymer.
10. The medical article of claim 1, wherein said microparticles comprise an inorganic material, and wherein said antimicrobial compound is dispersed within said inorganic material.

11. The medical article of claim 10, wherein said antimicrobial compound is dispersed within pores of said inorganic material.
12. The medical article of claim 1, wherein said microparticles comprise a silver-containing ion exchange material.
13. The medical article of claim 1, wherein said microparticles are silver-containing zeolite particles.
14. The medical article of claim 1, wherein said antimicrobial agent comprises silver.
15. The medical article of claim 1, wherein said latex polymer is formed from a natural latex.
16. The medical article of claim 1, wherein said latex polymer is formed from a synthetic latex.
17. The medical article of claim 16, wherein said synthetic latex is a pseudolatex.
18. The medical article of claim 1, wherein said release-modulating microparticles have an average largest dimension, on a weight average basis, ranging from 0.1 to 100 microns.
19. A process for providing the antimicrobial region of claim 1, comprising: (a) providing a latex comprising said microparticles, (b) contacting said latex with a substrate, and (c) curing said latex thereby forming said antimicrobial region.
20. The process of claim 19, wherein said substrate is a mold that is dipped into said latex.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/024558

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L29/16 A61L29/10 A61L31/16 A61L31/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, COMPENDEX, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/118664 A1 (TROGOLO JEFFREY A ET AL) 26 June 2003 (2003-06-26)	1,2,7-20
Y	paragraph '0017! - paragraph '0021! paragraphs '0028!, '0066!, '0069! examples 2,3,5	1-20
X	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 08, 29 August 1997 (1997-08-29) & JP 9 111053 A (HANAKI GOMME KK), 28 April 1997 (1997-04-28)	1,2, 10-20
Y	abstract	1-20
X	US 6 585 767 B1 (TROGOLO JEFFREY A ET AL) 1 July 2003 (2003-07-01) claims; examples	1,10-20
	----- -/-- -----	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

3 December 2004

Date of mailing of the international search report

21/12/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Winger, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/024558

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 180 585 A (JACOBSON HOWARD W ET AL) 19 January 1993 (1993-01-19)	1
Y	column 2, line 30 - line 50 column 8, line 40 - line 58 column 11, line 45 - line 65	1-20
A	----- MATSUMURA YOSHINOBU ET AL: "Mode of bactericidal action of silver zeolite and its comparison with that of silver nitrate." APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 69, no. 7, July 2003 (2003-07), pages 4278-4281, XP002308887 ISSN: 0099-2240 -----	

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US2004/024558

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2003118664	A1	26-06-2003	CA 2470122 A1 EP 1456291 A1 WO 03055941 A1	10-07-2003 15-09-2004 10-07-2003
JP 9111053	A	28-04-1997	JP 2740889 B2	15-04-1998
US 6585767	B1	01-07-2003	AU 3100600 A WO 0030567 A2	13-06-2000 02-06-2000
US 5180585	A	19-01-1993	WO 9415462 A1 AU 3441293 A DE 69321139 D1 DE 69321139 T2 EP 0677989 A1 JP 8505858 T US 5503840 A US 5643592 A US 5595750 A	21-07-1994 15-08-1994 22-10-1998 12-05-1999 25-10-1995 25-06-1996 02-04-1996 01-07-1997 21-01-1997